Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 2/20 | 0.34 |
| ▸ | CNR2 | P34972 | 8/20 | 0.34 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26610896 | 1.00 | KMT2A (0.36) | KMT2AMEN1ACHECNR2CNR1 | |
| SCHEMBL26611087 | 0.91 | KMT2A (0.37) | KMT2AMEN1ACHECNR2CNR1 | |
| SCHEMBL26611088 | 0.91 | KMT2A (0.37) | KMT2AMEN1ACHECNR2CNR1 | |
| SCHEMBL26696291 | 0.89 | NAMPT (0.38) | KMT2AMEN1 | |
| SCHEMBL26695989 | 0.80 | NAMPT (0.38) | KMT2AMEN1 | |
| SCHEMBL30630993 | 0.80 | NAMPT (0.38) | KMT2AMEN1 | |
| SCHEMBL23520755 | 0.78 | KMT2A (0.39) | KMT2AMEN1ACHECNR2LMNA | |
| SCHEMBL23520759 | 0.78 | KMT2A (0.39) | KMT2AMEN1ACHECNR2LMNA | |
| SCHEMBL23526211 | 0.77 | MEN1 (0.44) | KMT2AMEN1ACHEL3MBTL1LMNA | |
| SCHEMBL23526213 | 0.77 | MEN1 (0.44) | KMT2AMEN1ACHEL3MBTL1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240208975-A1 | MACROCYCLIC HETEROCYCLES AND USES THEREOF | KUMQUAT BIOSCIENCES INC. | 2024-06-27 | — | — | US | disclosed |
| US-11912708-B2 | Macrocyclic heterocycles and uses thereof | KUMQUAT BIOSCIENCES INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-20230339952-A1 | MACROCYCLIC HETEROCYCLES AND USES THEREOF | KUMQUAT BIOSCIENCES INC. | 2023-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240208975-A1 | MACROCYCLIC HETEROCYCLES AND USES THEREOF | HRAS, KRAS, TP53 | KMT2A 3278/4885MEN1 596/4885ACHE 4858/4885 |
| US-11912708-B2 | Macrocyclic heterocycles and uses thereof | HRAS, KRAS, TP53 | KMT2A 3278/4885MEN1 596/4885ACHE 4858/4885 |
| US-20230339952-A1 | MACROCYCLIC HETEROCYCLES AND USES THEREOF | HRAS, KRAS, TP53 | KMT2A 3278/4885MEN1 596/4885ACHE 4858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.